Mutation testing

Patent metadata

Field	Value
Publication number	US-9873913-B2
Application number	US-201414200522-A
Country	US
Kind code	B2
Filing date	Mar 7, 2014
Priority date	Mar 8, 2013
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

Improved methods of assessing status of a solid tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.

First claim

The invention claimed is:

1. A method of detecting a cancer-associated somatic mutation in a sample from a human subject with a solid tumor and administering treatment to the subject, comprising:
(a) obtaining the sample from the subject, wherein the subject has completed one or more cycles of a first targeted drug therapy, wherein the first targeted drug therapy targets the protein encoded by the nucleic acid having the cancer-associated somatic mutation;
(b) amplifying in a first real time PCR nucleic acids in the sample using an allele-specific primer pair specific for the cancer-associated somatic mutation and a primer pair specific for an internal control;
(c) generating a sample PCR threshold value for the cancer-associated somatic mutation, wherein the sample PCR threshold value is the number of cycles required in the first real time PCR to reach a predetermined signal magnitude for the cancer-associated somatic mutation, and generating a first internal control threshold value, wherein the first internal control threshold value is the number of cycles required in the first real time PCR to reach a predetermined signal magnitude for the internal control;
(d) amplifying in a second real time PCR DNA that does not carry the cancer-associated somatic mutation using the allele-specific primer pair specific for the cancer-associated somatic mutation and the primer pair specific for the internal control;
(e) generating a cut-off threshold value, wherein the cut-off threshold value is a breakthrough PCR cycle threshold, wherein the cut-off threshold value is the number of cycles required in the second real time PCR to reach the predetermined signal magnitude for the cancer-associated somatic mutation, and generating a second internal control threshold value, wherein the second internal control threshold value is the number of cycles required to reach the predetermined signal magnitude for the internal control;
(f) detecting a difference between the sample PCR threshold value and the first internal control PCR threshold value that is less than the difference between the cut-off threshold value and the second internal control value, thereby detecting the cancer-associated somatic mutation in the sample; and
(g) administering a second targeted drug therapy to the subject, wherein the second targeted drug therapy targets the protein encoded by the nucleic acid having the cancer-associated somatic mutation.

2. The method of claim 1 , wherein the first targeted drug therapy is a reversible tyrosine kinase inhibitor and the second targeted drug therapy is an irreversible kinase inhibitor.

3. A method of detecting a cancer-associated somatic mutation in a sample from a human subject with a solid tumor and administering treatment to the subject, comprising:
(a) obtaining the sample from the subject;
(b) amplifying in a first real time PCR nucleic acids in the sample using an allele-specific primer pair specific for the cancer-associated somatic mutation and a primer pair specific for an internal control;
(c) generating a sample PCR cycle threshold value for the cancer-associated somatic mutation, wherein the sample PCR cycle threshold value is the number of cycles required in the first real time PCR to reach a predetermined signal magnitude for the cancer-associated somatic mutation, and generating a first internal control threshold value, wherein the first internal control threshold value is the number of cycles required in the first real time PCR to reach a predetermined signal magnitude for the internal control;
(d) amplifying in a second real time PCR DNA that does not carry the cancer-associated somatic mutation using the allele-specific primer pair specific for the cancer-associated somatic mutation and the primer pair specific for the internal control;
(e) generating a cut-off threshold value, wherein the cut-off threshold value is a breakthrough PCR cycle threshold, wherein the cut-off threshold value is the number of cycles required in the second real time PCR to reach the predetermined signal magnitude for the cancer-associated somatic mutation, and generating a second internal control threshold value, wherein the second internal control threshold value is the number of cycles required to reach the predetermined signal magnitude for the internal control;
(f) detecting difference between the sample PCR threshold value and the first internal control PCR threshold value is less than the difference between the cut-off threshold value and the second internal control value, thereby detecting the cancer-associated somatic mutation in the sample;
(g) administering a first targeted drug therapy to the subject, wherein the first targeted drug therapy targets the protein encoded by the nucleic acid having the cancer-associated somatic mutation;
(h) repeating steps (a)-(f) after one or more cycles of the first targeted drug therapy;
(i1) reducing or continuing administration of the first targeted drug therapy if the sample PCR cycle threshold value of the cancer-associated somatic mutation in the sample from the subject before treatment with the first targeted drug therapy is lower than the sample PCR cycle threshold value in the sample from the subject after the one or more cycles of the first targeted drug therapy; or
(i2) administering a new treatment to the subject if the sample PCR cycle threshold value of the cancer-associated somatic mutation in the sample from the subject before treatment with the first targeted drug therapy is higher than the sample PCR cycle threshold value in the sample from the subject after the one or more cycles of the first targeted drug therapy, wherein the new treatment is surgery, chemotherapy, a second targeted drug therapy that targets the protein encoded by the nucleic acid having the cancer-associated somatic mutation, or any combination thereof.

4. The method of claim 3 , wherein the first targeted drug therapy is a reversible tyrosine kinase inhibitor and the second targeted drug therapy is an irreversible kinase inhibitor.

5. The method of claim 3 , wherein the first targeted drug therapy comprises administration of tyrosine kinase inhibitor selected from erlotinib or gefitinib.

6. The method of claim 3 , wherein the sample is a plasma sample.

7. The method of claim 3 , wherein the method further comprises performing a diagnostic procedure on the subject.

8. The method of claim 7 , wherein the diagnostic procedure is a radiological evaluation.

9. The method of claim 3 , wherein the solid tumor is lung cancer.

10. The method of claim 3 , wherein the DNA that does not carry the cancer-associated somatic mutation is genomic DNA.

11. The method of claim 1 , wherein the first targeted drug therapy comprises administration of tyrosine kinase inhibitor selected from erlotinib or gefitinib.

12. The method of claim 1 , wherein the sample is a plasma sample.

13. The method of claim 1 , wherein the method further comprises performing a diagnostic procedure on the subject.

14. The method of claim 13 , wherein the diagnostic procedure is a radiological evaluation.

15. The method of claim 1 , wherein the solid tumor is lung cancer.

16. The method of claim 1 , wherein the DNA that does not carry the cancer-associated somatic mutation is genomic DNA.

Assignees

• Roche Molecular Systems Inc

Inventors

• Klughammer Barbara
• Meldgaard Peter
• Sorensen Boe
• Tsai Julie
• Wen Wei
• Wu Lin

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title